Guggenheim analysts upgraded both Sanofi and Regeneron in part because of optimism about an antibody drug that treats a range of diseases on which the two companies have collaborated.

source https://finance.yahoo.com/m/a941ba0e-729f-39a0-ae5f-328698c340ca/sanofi-and-regeneron-stocks.html?.tsrc=rss